Company Overview and News

2
ATO / Atmos Energy Corp. / BlackRock Inc. - null (Passive Investment)

2018-09-07 sec.gov
us0495601058_090718.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ATMOS ENERGY CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 049560105 -------------------------------------------------------- (CUSIP Number) August 31, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this c
ATO

2
ATO / Atmos Energy Corp. / BlackRock Inc. - null (Passive Investment)

2018-09-07 sec.gov
us0495601058_090718.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ATMOS ENERGY CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 049560105 -------------------------------------------------------- (CUSIP Number) August 31, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this c
ATO

3
Why Is Atmos (ATO) Up 3.1% Since Last Earnings Report?

2018-09-07 zacks - 1
A month has gone by since the last earnings report for Atmos Energy (ATO - Free Report) . Shares have added about 3.1% in that time frame, outperforming the S&P 500.
ALLY TGI KORS ATO

2
ATO / Atmos Energy Corp. null

2018-08-16 sec.gov
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.C. 20549 Expires: June 30, 2020 Estimated average burden hours per response 1.00, FORM 144 SEC USE ONLY NOTICE OF PROPOSED SALE OF SECURITIES DOCUMENT SEQUENCE NO. PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale CUS1P NUMBER or executing a sale directly with a market maker.
ATO

2
ATO / Atmos Energy Corp. null

2018-08-16 sec.gov
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.C. 20549 Expires: June 30, 2020 Estimated average burden hours per response 1.00, FORM 144 SEC USE ONLY NOTICE OF PROPOSED SALE OF SECURITIES DOCUMENT SEQUENCE NO. PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale CUS1P NUMBER or executing a sale directly with a market maker.
ATO

2
Atmos Energy Corporation (ATO) CEO Mike Haefner on Q3 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Greetings, and welcome to Atmos Energy's Third Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] And as a reminder, this conference is being recorded.
ATO

3
Atmos Energy Corporation 2018 Q3 - Results - Earnings Call Slides

2018-08-09 seekingalpha - 1
The following slide deck was published by Atmos Energy Corporation in conjunction with their 2018 Q3 earnings call.
ATO

2
Atmos Energy (ATO) Q3 Earnings Miss, Revenues Improve Y/Y

2018-08-09 zacks
Atmos Energy Corporation (ATO - Free Report) posted third-quarter fiscal 2018 earnings of 64 cents per share, which missed the Zacks Consensus Estimate of 68 cents by 5.9%. Earnings also declined 4.5% from the prior-year quarter figure. Total Revenues Total revenues of $562.2 million lagged the Zacks Consensus Estimate of $637 million by 11.7%. However, total revenues improved 6.8% from $526.5 million in the prior-year quarter.
SRE NYLD OGS ATO UCTI AVD NYLD.A UCTT

4
Atmos Energy (ATO) Lags Q3 Earnings and Revenue Estimates

2018-08-08 zacks
Atmos Energy (ATO - Free Report) came out with quarterly earnings of $0.64 per share, missing the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.67 per share a year ago. These figures are adjusted for non-recurring items.
ACTG ATO FANG

2
ATO / Atmos Energy Corp. 10-Q (Quarterly Report)

2018-08-08 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ATO

40
Continue Snoozing On MDU Resources

2018-07-31 seekingalpha
There are two potential "growth kickers" that could translate into wins for the company and its shareholders.
SOJA SO GVA LNT STRL CQP UPS LNG NWE ATO BKH EME MYRG VVC VMC AVA PWR BKHU WACC MLM

10
ONE Gas (OGS) Q2 Earnings Surpass Estimates, 2018 View Up

2018-07-31 zacks
ONE Gas, Inc. (OGS - Free Report) posted second-quarter 2018 operating earnings of 39 cents per share, beating the Zacks Consensus Estimate of 32 cents by 21.9%. Earnings in the second quarter were positive impacted by colder-than-normal weather and new rates in its service territories. Total Revenues Total revenues of $292.5 million surpassed the Zacks Consensus Estimate of $275 million by 6.4%. Total revenues improved 4.
CWH AMKR OGS ATO EMES CPK

2
Should Victory CEMP US 500 Enhanced Volatility Wtd Index ETF (CFO) Be on Your Investing Radar?

2018-07-25 zacks
The Victory CEMP US 500 Enhanced Volatility Wtd Index ETF (CFO - Free Report) was launched on 07/01/2014, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Blend segment of the US equity market.
NOC ATO MS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ATO / Atmos Energy Corp. on message board site Silicon Investor.

John Pu0027s Market Laboratory John Pu0027s Market Laboratory John Pu0027s Market Laboratory College Football: Nits, Gators, Bruins, Vols - Whoever! College Football: Nits, Gators, Bruins, Vols - Whoever! College Football: Nits, Gators, Bruins, Vols - Whoever!
DLB Dolby Laboratories DLB Dolby Laboratories DLB Dolby Laboratories Gardening and Especially Tomato Growing Gardening and Especially Tomato Growing Gardening and Especially Tomato Growing
Ted Warrenu0027s Investolator Ted Warrenu0027s Investolator Ted Warrenu0027s Investolator The Epic American Credit and Bond Bubble Laboratory The Epic American Credit and Bond Bubble Laboratory The Epic American Credit and Bond Bubble Laboratory
Core Laboratories (CLB) Core Laboratories (CLB) Core Laboratories (CLB) HOT POTATO THREAD HOT POTATO THREAD HOT POTATO THREAD
Silver Wheaton (SLW) (Bulls Board) Silver Wheaton (SLW) (Bulls Board) Silver Wheaton (SLW) (Bulls Board) Celator Pharmaceuticals - CPXX Celator Pharmaceuticals - CPXX Celator Pharmaceuticals - CPXX
CUSIP: 049560105